Supportive Care

June 19, 2020
Simulation modeling demonstrated that prophylaxis of chemotherapy-induced febrile neutropenia with a supportive care biosimilar can lead to significant cost savings.
June 12, 2020
A study that tracked average reimbursement by CMS for a supportive care biosimilar may have a significant impact on an OCM practice’s performance.
December 31, 2019
Gary Lyman, MD, MPH, details why it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice and touches on issues of granting extrapolation.
September 11, 2019
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, explains why oncology biosimilar uptake in the US has been a lengthy process and whether these products will be viable options for payer-based and provider-based clinical pathways in the future.
July 02, 2019
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, president of ACCC, discusses his goals for his presidency, the common ground between standardized care and patient-centered care, and the role of biosimilars in treating patients with cancer in the immediate future.
April 30, 2019
In real-life practice in patients with NSCLC, a biosimilar product for chemotherapy-induced neutropenia demonstrates similar effectiveness and safety to that of the reference drug.
Guideline Updates
April 22, 2019
ASCO and ASH have issued an updated practice guideline on the use of erythropoiesis-stimulating agent biosimilars for patients with chemotherapy-associated anemia.
February 19, 2019
Doug Long, VP of industry relations at IQVIA, provided an update on trends in the generic and biosimilars market in the US and across the world at a recent conference.
November 13, 2018
Colony-stimulating growth factors biosimilars filgrastim-sndz and filgrastim-tbo are comparable in terms of safety and efficacy to the reference drug, researchers say.
August 30, 2018
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.